Marketplace Dynamics: Multiple Sclerosis assesses current and future access and prescribing landscapes for multiple sclerosis drugs, supporting identification of opportunities and risks for brands.
What level of influence do payers and organized providers have on access in the multiple sclerosis drugs market?
How will payer and organized provider management and contracting for branded multiple sclerosis drugs evolve over the next two years, and how should companies prepare for these changes?
How are payers responding to key events in the multiple sclerosis drugs market, such as new approvals and updated clinical data?
Use Marketplace Dynamics: Multiple Sclerosis to:
- Closely monitor market evolution
- Identify and monitor access shifts across the payer and organized provider segments
- Assess/predict payers' current and future management of the multiple sclerosis drugs market to facilitate development of effective strategies for inline/pipeline brand(s)
- Identify risks for brands, along with opportunities to improve access
-
Brand Access Influencers and Management Landscape – Multiple Sclerosis March
- Road map for improving access for branded multiple sclerosis drugs in 2021
- Analysis of stakeholder approaches to prioritizing and managing the multiple sclerosis drugs market
- Payer use of reimbursement, cost sharing, and utilization management tactics to influence use and restrict access of the multiple sclerosis drug market
- Brand-specific line-of-therapy requirements across multiple sclerosis indications
- Evolving management strategies for brands on the medical benefit, and evolving site-of-care management
- Role of PBMs and specialty pharmacies (SPs) under product selection, distribution, and management
-
Organized Provider Management and Evolving Payment Models – Multiple Sclerosis May
- Organized provider use of management tools and tactics to influence drug use and specialist treatment decisions
- Brand-specific line-of-therapy requirements across multiple sclerosis indications
- Prevalence of alternative payment models, innovative financial incentives, and performance metrics, along with associated impacts on drug access
-
Contracting Trends and Insights – Multiple Sclerosis July
- Impact and prevalence of contracting in the multiple sclerosis drugs market
- Key contracting terms and success factors driving access gains for branded multiple sclerosis drugs
- Evolution of risk-based contracting agreements for branded multiple sclerosis drugs
-
Outlook on Brand Access in 2024 – Multiple Sclerosis September
- Evolution of access in the branded multiple sclerosis drugs market
- Predicted management tactics for multiple sclerosis drugs at payers and organized providers by 2024
- Brand access predictions reflecting in-depth future scenarios with high likelihood of occurring